Nordea Investment Management AB Trims Stock Position in Danaher Corporation $DHR

Nordea Investment Management AB cut its position in shares of Danaher Corporation (NYSE:DHR) by 1.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,763,580 shares of the conglomerate’s stock after selling 19,955 shares during the period. Nordea Investment Management AB’s holdings in Danaher were worth $352,222,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Praxis Investment Management Inc. raised its stake in Danaher by 3.2% during the second quarter. Praxis Investment Management Inc. now owns 29,374 shares of the conglomerate’s stock worth $5,803,000 after purchasing an additional 920 shares during the period. Harbor Asset Planning Inc. purchased a new position in Danaher during the second quarter worth about $153,000. Turtle Creek Wealth Advisors LLC purchased a new position in Danaher during the second quarter worth about $328,000. Dash Acquisitions Inc. raised its stake in Danaher by 2.6% during the second quarter. Dash Acquisitions Inc. now owns 81,185 shares of the conglomerate’s stock worth $16,066,000 after purchasing an additional 2,070 shares during the period. Finally, Generali Asset Management SPA SGR raised its stake in shares of Danaher by 15.0% in the 2nd quarter. Generali Asset Management SPA SGR now owns 62,997 shares of the conglomerate’s stock valued at $12,444,000 after acquiring an additional 8,237 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of DHR opened at $210.86 on Friday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.41. The firm’s 50 day moving average price is $201.43 and its 200 day moving average price is $197.23. The company has a market cap of $150.99 billion, a P/E ratio of 44.86, a PEG ratio of 2.94 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the prior year, the firm earned $1.72 EPS. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s payout ratio is 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DHR shares. Bank of America reduced their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. UBS Group reduced their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price target (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $244.60.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.